Translating FDA for Investors: Seattle Genetics Shrugs Off Public Lambasting at ODAC
This article was originally published in RPM Report
Executive Summary
Actions speak louder than words. That, at least, is how Seattle Genetics urged investors to think about a tongue lashing the company received during an advisory committee review of the cancer agent Adcetris Seattle Genetics may be right on two levels: the practical outcome of the meeting was positive, and the FDA rhetoric may not have been as directly aimed at the sponsor as a warning to all oncology drug developers.
You may also be interested in...
Another Vote for Accelerated Approval
The Oncologic Drugs Advisory Committee review of ApoPharma’s Ferriprox was not one of the highest profile meetings of the past year. But for sponsors concerned about the availability of the accelerated approval pathway, it was a very important event.
Who You Gonna Call?
If Adcetris does not reach the market under accelerated approval by Labor Day, it may be because the company’s management team made the wrong call on the morning of July 15.
Accelerated Withdrawal in Action: The Avastin Hearing Process
The June hearing on the status of Genentech’s metastatic breast cancer indication for Avastin will focus on a long list of substantive disagreements about the data. But any sponsor interested in the future of the accelerated approval process should study the back-and-forth in the hearing process itself.